Ki-67 Cancer Research Results
Ki-67, Ki-67 protein: Click to Expand ⟱
| Source: |
| Type: proliferation marker |
A high Ki-67 proliferation index means many cells are dividing quickly and that the cancer is likely to grow and spread.
Markers of proliferation index (Ki-67)
• Ki-67 serves primarily as a proliferation marker: higher levels are generally indicative of aggressive disease and poorer outcomes across many cancer types.
• While Ki-67 itself is not considered a driver of tumorigenesis, its expression mirrors the high proliferative activity associated with protumoral behavior.
• It is widely used in clinical practice to aid in tumor grading, prognostication, and treatment planning.
|
Melanoma, Melanoma Skin Cancer: Click to Expand ⟱
Melanoma is a rare form of skin cancer. It is more likely to invade nearby tissues and spread to other parts of the body than other types of skin cancer.
|
Scientific Papers found: Click to Expand⟱
| - |
in-vitro, |
Melanoma, |
SK-MEL-28 |
|
|
|
- |
in-vitro, |
Melanoma, |
A375 |
|
|
|
LDHA↓, ENO1↓, PKM2↓, GLUT1↓, GLUT3↓, HK2↓, PFK1↓, GPI↓, TPI↓, GlucoseCon↓, TumCG↓, TumCP↓, mTORC1↓, Hif1a↓, Ki-67↓,
| - |
in-vivo, |
Melanoma, |
B16-BL6 |
|
|
|
eff↑, Ki-67↓, TumCP↓, Apoptosis↑, TumCG↓,
| - |
in-vivo, |
Melanoma, |
U266 |
|
|
|
- |
in-vivo, |
Melanoma, |
RPMI-8226 |
|
|
|
eff↑, NF-kB↓, PI3K↓, Akt↓, AP-1↓, COX2/PTGS2↓, MMP9↓, Casp3↑, cl‑PARP↑, Dose↝, Ki-67↓, VEGF↓,
| - |
vitro+vivo, |
Melanoma, |
SK-MEL-28 |
|
|
|
- |
vitro+vivo, |
Melanoma, |
A375 |
|
|
|
OS↑, TumCP↓, Ki-67↓, TumCP↓, Gli1↓, GLI2↓, Wnt↓, β-catenin/ZEB1↓, cycD1/CCND1↓, AXIN1↑, GLI3↑, AXIN1↑, HH↓, PI3K↓, Akt↓, *toxicity↓,
| - |
in-vitro, |
Melanoma, |
A431 |
|
|
|
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, AntiTum↑, cal2↑, cl‑β-catenin/ZEB1↑, cl‑Casp12↑, Bcl-2↓, cycD1/CCND1↓, CDK2↓, BAX↑, TumCCA↑, selectivity↑, N-cadherin↓, E-cadherin↑, Ki-67↓, PCNA↑,
Showing Research Papers: 1 to 5 of 5
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5
Pathway results for Effect on Cancer / Diseased Cells:
Core Metabolism/Glycolysis(tgid=4) ⓘ
ENO1↓, 1, GlucoseCon↓, 1, GPI↓, 1, HK2↓, 1, LDHA↓, 1, PFK1↓, 1, PKM2↓, 1, TPI↓, 1,
Cell Death(tgid=5) ⓘ
Akt↓, 2, Apoptosis↑, 2, BAX↑, 1, Bcl-2↓, 1, cl‑Casp12↑, 1, Casp3↑, 1,
DNA Damage & Repair(tgid=10) ⓘ
cl‑PARP↑, 1, PCNA↑, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
CDK2↓, 1, cycD1/CCND1↓, 2, TumCCA↑, 1,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
AXIN1↑, 2, EMT↓, 1, Gli1↓, 1, HH↓, 1, mTORC1↓, 1, PI3K↓, 2, TumCG↓, 2, Wnt↓, 1,
Migration(tgid=13) ⓘ
AP-1↓, 1, cal2↑, 1, E-cadherin↑, 1, GLI2↓, 1, GLI3↑, 1, Ki-67↓, 5, MMP9↓, 1, N-cadherin↓, 1, TumCI↓, 1, TumCMig↓, 1, TumCP↓, 5, β-catenin/ZEB1↓, 1, cl‑β-catenin/ZEB1↑, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
Hif1a↓, 1, VEGF↓, 1,
Barriers & Transport(tgid=15) ⓘ
GLUT1↓, 1, GLUT3↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
COX2/PTGS2↓, 1, NF-kB↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
Dose↝, 1, eff↑, 2, selectivity↑, 1,
Clinical Biomarkers(tgid=22) ⓘ
Ki-67↓, 5,
Functional Outcomes(tgid=23) ⓘ
AntiTum↑, 1, OS↑, 1,
Total Targets: 52
Pathway results for Effect on Normal Cells:
Functional Outcomes(tgid=23) ⓘ
toxicity↓, 1,
Total Targets: 1
Scientific Paper Hit Count for: Ki-67, Ki-67 protein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:39 Cells:% prod#:% Target#:425 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid
Home Page